Mohammad Jafarnejad

Mohammad Jafarnejad is an accomplished scientist with extensive experience in quantitative pharmacology and systems pharmacology. At Genentech, from October 2019 to April 2021, Mohammad developed QSP models for novel cytokine therapies and mechanistic PKPD models in neurodegeneration. Following this, at Denali Therapeutics from April 2021 to November 2023, Mohammad held the position of Head of Quantitative Pharmacology and contributed to multiple programs by leading roles in LMPK, modeling and simulations, and clinical pharmacology. Prior to this, Mohammad completed a postdoctoral fellowship at The Johns Hopkins University School of Medicine, focusing on quantitative systems pharmacology for anti-tumor immune responses, and a graduate research assistantship at Imperial College London, where research involved chemokine receptor roles in lymph transport. Mohammad holds a Ph.D. in Bioengineering from Imperial College London and an M.Sc. in Biomedical Engineering from Texas A&M University.